Researchers report that tenapanor — a small molecule inhibitor of the sodium/hydrogen exchanger isoform 3 — reduces serum phosphate levels in patients with hyperphosphataemia receiving haemodialysis. In this double-blind trial, 162 patients underwent washout of phosphate binders before being randomly assigned to receive either tenapanor or placebo for 4 weeks. Tenapanor treatment resulted in significant dose-dependent reductions in serum phosphate levels from baseline. The most common adverse event was diarrhoea.
References
Block, G. A. et al. Effect of tenapanor on serum phosphate in patients receiving haemodialysis. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2016080855 (2017)
Rights and permissions
About this article
Cite this article
Carney, E. Efficacy of tenapanor in hyperphosphataemia. Nat Rev Nephrol 13, 194 (2017). https://doi.org/10.1038/nrneph.2017.27
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2017.27